Orchestra BioMed Holdings (OBIO) Total Non-Current Liabilities (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Total Non-Current Liabilities for 6 consecutive years, with $49.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 17.18% year-over-year to $49.3 million; the TTM figure through Mar 2026 stood at $49.3 million (up 17.18% YoY), while the FY2025 annual figure was $51.2 million, up 18.52% from the prior year.
• Total Non-Current Liabilities eased to $49.3 million in Q1 2026 per OBIO's latest filing, from $51.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $60.8 million in Q3 2025 and bottomed at $5.3 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $40.5 million across 5 years, with a median of $42.3 million in 2025.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 735.04% — and 2026, when it rose 17.18%.
• Orchestra BioMed Holdings' Total Non-Current Liabilities stood at $42.8 million in 2022, then declined by 14.95% to $36.4 million in 2023, then increased by 18.5% to $43.2 million in 2024, then increased by 18.52% to $51.2 million in 2025, then retreated by 3.61% to $49.3 million in 2026.
• Business Quant data shows OBIO's Total Non-Current Liabilities at $49.3 million in Q1 2026, $51.2 million in Q4 2025, and $60.8 million in Q3 2025.